IPO
Basel-based Medartis announced plans to IPO on the SIX Swiss Exchange, with funds to support the company’s growth strategy. Medartis recorded sales of CHF 105 million (~$110 million) and EBITDA of CHF 19 million (~$20 million) in 2017 and says the time is right for the trauma fixation company to grow, according to a report in Fierce Medtech.
Among its plans for the funds are introducing new products over the next couple of years as well as expanding existing products into new indications and markets.
Posted: March 02, 2018
